Glipizide
Glipizide. Second-generation sulfonylurea — closes pancreatic β-cell K-ATP channels → depolarization → Ca²⁺ influx → insulin release. Hypoglycemia… Oral half-life 5 h.
Second-generation sulfonylurea — closes pancreatic β-cell K-ATP channels → depolarization → Ca²⁺ influx → insulin release. Hypoglycemia risk + weight gain. CYP2C9 substrate; renal-safe relative to glyburide.
PK: SMALL, REAL AND ENTIRELY DECIDABLE INSIDE ONE ABSTRACT. The stored half-life appears nowhere — its own citation says "t1/2 = 5.0 +/- 2.3 vs. 5.2 +/- 2.0 h" — and the clearance test runs entirely within that same paper, which states "CL/F, 2.3 +/- 1.0 vs. 2.0 +/- 1.0 L/h" against a stored assertion 47 percent higher. SUBSTITUTING THE ONE VERBATIM VALUE CUTS THE ERROR BY TWO THIRDS. The volume is verbatim but is the OBESE ARM of a two-arm study, rendered here at the seventy-kilogram reference while the non-obese figure is equally verbatim and closer to that reference — recorded, not changed, since the difference is inside the reported spread. MY SAME-CLASS COLLISION PRIOR IS REFUTED: checked in both directions against glimepiride, there is no shared or near-shared numeral, and the only value the two have in common is an absorption rate they also share with an unrelated record, most likely two independent guesses at fast absorption. A FORMULATION FLAG IS LOGGED: the stored dose range matches the extended-release ceiling while the cited study is unambiguously immediate-release, and a zero-order duration would be the honest way to carry that.
Pharmacokinetics
- Oral — t½ 5 h · F 100% · ka 0.6238 h⁻¹ · Vd 19.5 L
Sources: PMID:8848822